What phase III trials are needed to improve the treatment of advanced non-small-cell lung cancer?

Nagahiro Saijo

doi:10.1038/ncponc0199 | Full Text | PDF (52K)

Duration of adjuvant therapy for colorectal cancer: are we overtreating our patients?

Sharlene Gill and Richard M Goldberg

doi:10.1038/ncponc0192 | Full Text | PDF (72K)

Thiopurine methyltransferase genotype and childhood acute lymphoblastic leukemia

doi:10.1038/ncponc0181 | Full Text | PDF (51K)

Link between high human papillomavirus load and invasive cervical cancer

doi:10.1038/ncponc0182 | Full Text | PDF (51K)

Bortezomib and pegylated liposomal doxorubicin: phase I trial in patients with advanced hematologic malignancies

doi:10.1038/ncponc0183 | Full Text | PDF (58K)

Biochemical failure following prostate cancer treatment

doi:10.1038/ncponc0184 | Full Text | PDF (48K)

Gemcitabine plus capecitabine in biliary cancer

doi:10.1038/ncponc0185 | Full Text | PDF (60K)

Role of activated protein kinase B in melanoma

doi:10.1038/ncponc0186 | Full Text | PDF (53K)

Tamoxifen for breast cancer risk reduction: an evaluation of women's preferences

doi:10.1038/ncponc0187 | Full Text | PDF (60K)

Hematopoietic stem-cell transplantation in mantle-cell lymphoma

doi:10.1038/ncponc0188 | Full Text | PDF (51K)

Elevated rectal cancer risk following prostate radiation

doi:10.1038/ncponc0189 | Full Text | PDF (51K)

Social activity in infancy protects against childhood acute lymphoblastic leukemia

doi:10.1038/ncponc0190 | Full Text | PDF (64K)

Chemotherapy-related acute promyelocytic leukemia: role of topoisomerase II

doi:10.1038/ncponc0193 | Full Text | PDF (57K)

Role of ARLTS1 in familial cancer

doi:10.1038/ncponc0194 | Full Text | PDF (65K)

Do patient preferences reduce the validity of randomized trials?

doi:10.1038/ncpcardio0187 | Full Text | PDF (51K)

Relationship between birth weight and cancer risk

doi:10.1038/ncponc0197 | Full Text | PDF (51K)

Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?

José Baselga

doi:10.1038/ncponc0165 | Full Text | PDF (73K)

Temporal trends in ovarian cancer: incidence and mortality across Europe

Wendy R Brewster

doi:10.1038/ncponc0198 | Full Text | PDF (67K)

Nadir CA125 concentration as a prognostic indicator in ovarian cancer

Andre T Baron and Nita Maihle

doi:10.1038/ncponc0178 | Full Text | PDF (75K)

What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer?

Amir Onn and Roy S Herbst

doi:10.1038/ncponc0191 | Full Text | PDF (69K)

What are the prognostic factors for survival in patients with metastatic renal cell carcinoma?

Brian I Rini

doi:10.1038/ncponc0180 | Full Text | PDF (69K)

Does hematopoietic stem cell transplantation improve patient outcome in juvenile myelomonocytic leukemia?

Norbert Schmitz

doi:10.1038/ncponc0179 | Full Text | PDF (68K)

Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer

Eric B Haura, James Turkson and Richard Jove

doi:10.1038/ncponc0195 | Full Text | PDF (450K)